No new safety signals in ofatumumab open-label data

Only a few weeks prior to the MSVirtual 2020, the fully human anti-CD20 monoclonal antibody ofatumumab was approved by the FDA for the treatment of relapsing forms of MS. In the open-label extension study ALITHIOS, ofatumumab's very good safety profile was consistent with data from the core phase 3 ASCLEPIOS I/ASCLEPIOS II trials [1,2]. The indication of ofatumumab is to include clinically isolated syndrome (CIS), relapsing-remitting MS, and active secondary progressive MS in adults. In the ASCLEPIOS trials, ofatumumab demonstrated superior efficacy ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 25 November, 2020